Table 3.
Prognostic factors in univariate analysis
| N | 2-year PFS | 2-year OS | ||||
|---|---|---|---|---|---|---|
| % | P | % | P | |||
| Sex | 0.135 | 0.062 | ||||
| Male | 58 | 57.9 | 73.5 | |||
| Female | 21 | 78.5 | 88.4 | |||
| Subtype of pathology | 0.410 | 0.538 | ||||
| ALCL ALK+ | 18 | 77.8 | 83.0 | |||
| ALCL ALK- | 9 | 55.6 | 64.8 | |||
| ALCL ALK unknown | 5 | 80.0 | 100.0 | |||
| PTCL | 10 | 57.1 | 64.8 | |||
| AITL | 14 | 74.3 | 92.9 | |||
| NKTCL | 21 | 54.5 | 60.1 | |||
| SPTCL-αβ | 1 | 0.0 | 0.0 | |||
| SPTCL-γδ | 1 | 0.0 | 100.0 | |||
| ECOG | 0.268 | 0.269 | ||||
| 0 | 48 | 65.3 | 76.8 | |||
| 1 | 27 | 55.5 | 65.0 | |||
| 2 | 4 | 100.0 | 100.0 | |||
| Stage | ||||||
| Stage I | 4 | 50.0 | 0.825 | 50.0 | 0.536 | |
| Stage II | 15 | 57.0 | 67.9 | |||
| Stage III | 15 | 71.8 | 86.2 | |||
| Stage IV | 45 | 64.0 | 73.8 | |||
| B Symptom | 0.738 | 0.743 | ||||
| No | 38 | 65.6 | 76.6 | |||
| Yes | 41 | 61.8 | 71.6 | |||
| Extranodal sites | 0.691 | 0.862 | ||||
| ≤1 | 45 | 67.4 | 74.7 | |||
| >1 | 34 | 58.5 | 72.9 | |||
| LDH before treatment | 0.393 | 0.327 | ||||
| Normal (≤240U/L) | 31 | 58.4 | 67.4 | |||
| Elevated (>240U/L) | 26 | 63.8 | 75.8 | |||
| Unknown | 22 | - | - | |||
| β2-MG before treatment | 0.420 | 0.238 | ||||
| Normal (≤3.0mg/L) | 35 | 63.1 | 73.5 | |||
| Elevated (>3.0mg/L) | 16 | 53.5 | 62.7 | |||
| Unknown | 28 | - | - | |||
| ESR before treatment | 0.140 | 0.035 | ||||
| Normal (≤15mm/h) | 28 | 66.7 | 80.8 | |||
| Elevated (>15mm/h) | 24 | 46.3 | 56.2 | |||
| Unknown | 27 | - | - | |||
| aaIPI | 0.537 | 0.215 | ||||
| 0 | 7 | 57.1 | 71.4 | |||
| 1 | 26 | 58.2 | 61.5 | |||
| 2 | 23 | 67.2 | 81.4 | |||
| LDH unknown or age>60 | 23 | - | - | |||
| PIT | 0.770 | 0.691 | ||||
| 0 | 27 | 59.5 | 67.3 | |||
| 1 | 26 | 59.3 | 75.4 | |||
| 2 | 4 | 75.0 | 66.7 | |||
| Unknown | 22 | - | - | |||
| Response before HDT/ASCT | <0.001 | <0.001 | ||||
| CR1 | 38 | 85.8 | 94.2 | |||
| PR1 | 9 | 76.2 | 72.9 | |||
| CR2 | 10 | 43.8 | 77.1 | |||
| PR2 | 12 | 28.1 | 46.3 | |||
| SD/PD | 10 | 30.0 | 36.0 | |||
| LDH before HDT/ASCT | 0.019 | 0.728 | ||||
| Normal (≤240U/L) | 67 | 67.9 | 74.6 | |||
| Elevated (>240U/L) | 11 | 34.1 | 65.5 | |||
| Unknown | 1 | - | - | |||
| β2-MG before HDT/ASCT | 0.146 | 0.028 | ||||
| Normal (≤3.0mg/L) | 55 | 68.8 | 80.7 | |||
| Elevated (>3.0mg/L) | 10 | 60.0 | 57.1 | |||
| Unknown | 14 | - | - | |||
| ESR before HDT/ASCT | 0.003 | 0.001 | ||||
| Normal (≤15mm/h) | 36 | 79.8 | 91.3 | |||
| Elevated (>15mm/h) | 24 | 47.9 | 52.3 | |||
| Unknown | 19 | - | - | |||
PFS: progression free survival; OS: overall survival; ALCL: Anaplastic large-cell lymphoma; ALK+: Anaplastic lymphoma kinase expressing; ALK-: without anaplastic lymphoma kinase expressing; PTCL-NOS: Peripheral T-cell lymphoma, not otherwise specified; AITL: Angioimmunoblastic T-cell lymphoma; NKTCL: extranodal natural killer/T-cell lymphoma, nasal type; SPTCL: Subcutaneous panniculitis-like T-cell lymphoma; ECOG PS: Eastern Cooperative Oncology Group performance status; LDH: Lactate dehydrogenase; β2-MG: β2-Microglobulin; ESR: Erythrocyte sedimentation rate; aaIPI: age adjusted International Prognostic Index; PIT: Prognostic Index for T-cell lymphoma; HDT/ASCT: High-dose therapy and autologous stem cell transplantation; CR1: complete remission after first-line treatment; PR1: partial remission after first-line treatment; CR2: complete remission after second-line treatment; PR2: partial remission after second-line treatment; SD: Stable disease; PD: Progressive disease.